The combination of mTORC1/2 and PI3Kα inhibition alleviates PI3K pathway reactivation and leads to significant antitumor activity in multiple preclinical xenograft models.

被引：1
|
作者：
Brake, Rachael L. [1 ]
Fabrey, Robyn [2 ]
Szwaya, Jeff [1 ]
Fitzgerald, Michael [1 ]
Iartchouk, Natasha [1 ]
Guo, Xin [2 ]
Kuida, Keisuke [1 ]
Zohren, Fabian [1 ]
Manfredi, Mark [1 ]
机构：
[1] Takeda, Cambridge, MA USA
[2] Takeda Calif, San Diego, CA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2013年 / 12卷 / 11期
关键词：
D O I：
10.1158/1535-7163.TARG-13-C176
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C176
引用
收藏
页数：1
相关论文
共 50 条
  • [21] VS-5584 a dual mTORC1/2 and PI3K inhibitor has anti-tumor activity in multiple in vivo xenograft tumor models and enhanced efficacy in combination with cisplatin or docetaxel
    Trombino, Anthony F.
    Kolev, Vihren N.
    Wright, Quentin G.
    Xu, Qunli
    Padval, Mahesh V.
    CANCER RESEARCH, 2014, 74 (19)
  • [22] Are Wnt/β-Catenin and PI3K/AKT/mTORC1 Distinct Pathways in Colorectal Cancer?
    Prossomariti, Anna
    Piazzi, Giulia
    Alquati, Chiara
    Ricciardiello, Luigi
    CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, 2020, 10 (03): : 491 - 506
  • [23] MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer
    Garcia-Garcia, Celina
    Rivas, Martin A.
    Ibrahim, Yasir H.
    Teresa Calvo, Maria
    Gris-Oliver, Albert
    Rodriguez, Olga
    Grueso, Judit
    Anton, Pilar
    Guzman, Marta
    Aura, Claudia
    Nuciforo, Paolo
    Jessen, Katti
    Argiles, Guillem
    Dienstmann, Rodrigo
    Bertotti, Andrea
    Trusolino, Livio
    Matito, Judit
    Vivancos, Ana
    Chicote, Irene
    Palmer, Hector G.
    Tabernero, Josep
    Scaltriti, Maurizio
    Baselga, Jose
    Serra, Violeta
    CLINICAL CANCER RESEARCH, 2015, 21 (24) : 5499 - 5510
  • [24] Antitumor activity of a dual PI3K and HDAC inhibitor in hematologic cancer models
    Bao, Rudi
    Wang, Dagong
    Qu, Hui
    Yin, Ling
    Xu, Guang-Xin
    DellaRocca, Steven
    Borek, Mylissa
    Atoyan, Ruzanna
    Forrester, Jeffrey
    Samson, Maria
    Wang, Jing
    Zhai, Hai-Xaio
    Chan, Mendy
    Lai, Cheng-Jung
    Cai, Xiong
    Qian, Changgeng
    CANCER RESEARCH, 2011, 71
  • [25] Asymmetric PI3K Activity in Lymphocytes Organized by a PI3K-Mediated Polarity Pathway
    Chen, Yen-Hua
    Kratchmarov, Radomir
    Lin, Wen-Hsuan W.
    Rothman, Nyanza J.
    Yen, Bonnie
    Adams, William C.
    Nish, Simone A.
    Rathmell, Jeffrey C.
    Reiner, Steven L.
    CELL REPORTS, 2018, 22 (04): : 860 - 868
  • [26] Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention
    Davis, Nicole M.
    Sokolosky, Melissa
    Stadelman, Kristin
    Abrams, Stephen L.
    Libra, Massimo
    Candido, Saverio
    Nicoletti, Ferdinando
    Polesel, Jerry
    Maestro, Roberta
    D'Assoro, Antonino
    Drobot, Lyudmyla
    Rakus, Dariusz
    Gizak, Agnieszka
    Laidler, Piotr
    Dulinska-Litewka, Joanna
    Basecke, Joerg
    Mijatovic, Sanja
    Maksimovic-Ivanic, Danijela
    Montalto, Giuseppe
    Cervello, Melchiorre
    Fitzgerald, Timothy L.
    Demidenko, Zoya N.
    Martelli, Alberto M.
    Cocco, Lucio
    Steelman, Linda S.
    McCubrey, James A.
    ONCOTARGET, 2014, 5 (13) : 4603 - 4650
  • [27] Rational for specific inhibition of both PI3K/AKT and mTORC1 activities in acute myelogenous leukaemia.
    Tamburini, Jerome
    Chapuis, Nicolas
    Bardet, Valerie
    Park, Sophie
    Verdier, Frederique
    Dreyfus, Francois
    Lacombe, Catherine
    Bouscary, Didier
    BLOOD, 2006, 108 (11) : 539A - 540A
  • [28] PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo
    Niessner, Heike
    Schmitz, Jennifer
    Tabatabai, Ghazaleh
    Schmid, Andreas M.
    Calaminus, Carsten
    Sinnberg, Tobias
    Weide, Benjamin
    Eigentler, Thomas K.
    Garbe, Claus
    Schittek, Birgit
    Quintanilla-Fend, Leticia
    Bender, Benjamin
    Mai, Marion
    Praetorius, Christian
    Beissert, Stefan
    Schackert, Gabriele
    Muders, Michael H.
    Meinhardt, Matthias
    Baretton, Gustavo B.
    Dummer, Reinhard
    Flaherty, Keith
    Pichler, Bernd J.
    Kulms, Dagmar
    Westphal, Dana
    Meier, Friedegund
    CLINICAL CANCER RESEARCH, 2016, 22 (23) : 5818 - 5828
  • [29] SPR965, a PI3K/mTORC1/C2 inhibitor for treatment of chordoma
    Dugar, Sundeep
    Sen, Somdutta
    Maffuid, Paul
    Freed, Dan
    Sommer, Josh
    Anderson, Edward
    Hickey, Anthony
    CANCER RESEARCH, 2022, 82 (12)
  • [30] SPR965, a PI3K/mTORC1/2 inhibitor, as a targeted therapy in endometrial cancer
    Sullivan, S. A.
    Tran, A. Q.
    Yin, Y.
    Fang, Z.
    Chan, L.
    Zhou, C.
    Dugar, S.
    Bae-Jump, V. L.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 171 - 171
12345